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Abstract
Dihydropyridines (DHPs) are L-type calcium channel (Cav1) blockers prescribed to treat several diseases including
hypertension. Cav1 channels normally exist in three states: a resting closed state, an open state that is triggered by
membrane depolarization, followed by a non-conducting inactivated state that is triggered by the influx of calcium ions,
and a rapid change in voltage. DHP binding is thought to alter the conformation of the channel, possibly by engaging a
mechanism similar to voltage dependent inactivation, and locking a calcium ion in the pore, thereby blocking channel
conductance. As a Cav1 channel crystal structure is lacking, the current model of DHP action has largely been achieved by
investigating the role of candidate Cav1 residues in mediating DHP-sensitivity. To better understand DHP-block and identify
additional Cav1 residues important for DHP-sensitivity, we screened 440,000 randomly mutated Caenorhabditis elegans
genomes for worms resistant to DHP-induced growth defects. We identified 30 missense mutations in the worm Cav1 pore-
forming (a1) subunit, including eleven in conserved residues known to be necessary for DHP-binding. The remaining
polymorphisms are in eight conserved residues not previously associated with DHP-sensitivity. Intriguingly, all of the worm
mutants that we analyzed phenotypically exhibited increased channel activity. We also created orthologous mutations in
the rat a1C subunit and examined the DHP-block of current through the mutant channels in culture. Six of the seven mutant
channels examined either decreased the DHP-sensitivity of the channel and/or exhibited significant residual current at DHP
concentrations sufficient to block wild-type channels. Our results further support the idea that DHP-block is intimately
associated with voltage dependent inactivation and underscores the utility of C. elegans as a screening tool to identify
residues important for DHP interaction with mammalian Cav1 channels.
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Introduction
Calcium influx into the cell can make both an immediate and a
long-term impact on many cellular processes, including membrane
excitability, neurotransmitter release, muscle contraction, tran-
scription, and proliferation [1]. It is therefore not surprising that
calcium current through calcium-permeable channels is tightly
regulated. Calcium channels of the Cav family, for example,
regulate current through voltage dependent mechanisms and exist
in three major biophysical states: a resting (non-conducting) state,
an activated (conducting) state that is triggered by a rapid change
of voltage, and an inactivated (non-conducting) state that follows
the conducting state but is refractory to activation. Cav channels
are composed of multiple subunits that regulate calcium current
through the pore-forming and voltage-sensing a1 subunit, which
has four repeating domains (called I–IV), each with six
transmembrane segments designated S1–S6 [2,3] (Figure 1). The
most widely-expressed Cav channels are the L-type, otherwise
known as Cav1 channels. In humans, alterations in Cav1
abundance or function result in a variety of diseases, including
hypertension [4], Timothy Syndrome [5], and congenital
stationary night blindness [6]. A better understanding of Cav1
function and how this function can be modulated by drug-like
molecules may therefore lead to better treatments of Cav1-related
diseases.
A distinguishing feature of Cav1 channels is their sensitivity to
1,4-dihydropyridines (DHPs), which bind to the a1 subunit and are
commonly prescribed to reduce hypertension in humans [7].
Exactly how DHPs physically interact with the a1 subunit is
incompletely understood, in large part because the crystal
PLoS Genetics | www.plosgenetics.org 1 May 2008 | Volume 4 | Issue 5 | e1000067structure of any Cav1 a1 subunit remains elusive. However, Cav1
residues that facilitate DHP interaction have been identified
through the analyses of candidate domains and residues. For
example, swapping domains IIIS5, IIIS6, and IVS5-IVS6 from an
L-type to a non-L-type channel is sufficient to confer DHP-
sensitivity to otherwise insensitive Cav channels [8,9,10]. Individ-
ual Cav1 residues present in DHP-sensitive, but not insensitive
channels, have also been extensively investigated to determine if
they are necessary and sufficient for DHP-sensitivity [11,12,13,14].
In this way, four residues in domain IS6, two residues in IIIS5,
eight residues in IIIS6, and six residues in IVS6 were shown to be
important for DHP binding to the a1 subunit of the Cav1 channel
in culture [11,14,15,16,17,18] (summarized in Table 1).
DHPs are thought to block calcium current by inducing
allosteric structural changes in the channel that engages the
channel in the inactivated state [18,19] and promotes high affinity
interaction with a single calcium ion within the pore [20,21,22],
thereby preventing further ion flow. Calcium ions are bound by
the channel through four negatively charged glutamate residues
(called the calcium selectivity filter), which reside within four
membrane-embedded intersegmental loops between S5 and S6
(called SS1–SS2) of each domain (Table 1). Together, the four
SS1–SS2 domains form the extracellular-facing ‘outer pore’ of the
channel (see Figure 1). The relationship between the DHP and the
selectivity filter is bidirectional: DHP-binding facilitates a high
affinity interaction between the selectivity filter and a calcium ion,
and the coupling of the selectivity filter to calcium promotes a
high-affinity interaction between the DHP and the channel
[21,23,24]. A candidate analysis of residues surrounding the
glutamate selectivity filter revealed several residues that are also
important for high-affinity DHP interaction with the channel in
culture [21,24,25,26] (Table 1).
Clearly, the candidate approach has been fruitful in identifying
residues important for DHP antagonism of Cav1 channels.
However, as the exact molecular mechanism of DHP block
remains incompletely understood, the search for additional
residues involved in DHP-sensitivity might add to our under-
standing of DHP-Cav1 interaction. We therefore screened random
mutants of the tiny nematode worm C. elegans for those animals
that are resistant to the effects of a novel DHP analog called
nemadipine in the hopes of identifying new Cav1 residues
important for DHP-sensitivity.
We recently discovered nemadipine through a screen for new
biologically active small molecules [27,28]. Through a variety of
genetic approaches, we demonstrated that the major target of
nemadipine is EGL-19 [27], which is the sole Cav1 channel a1
subunit encoded by the C. elegans genome [29]. We also found that
nemadipine can antagonize vertebrate Cav1 channels with a
similar potency as an FDA-approved DHP in chick ciliary neurons
[27]. However, none of the FDA-approved Cav1 antagonists
examined, including nifedipine, nicardipine, felodipine, and
nimodipine, elicit robust phenotypes in whole worms. Worm
insensitivity to these DHPs is not likely due to Cav1 divergence
since nifedipine can antagonize EGL-19 in dissected worms [29].
Instead, we discovered that most FDA-approved DHPs fail to
accumulate in whole worms [27], consistent with the idea that C.
elegans has extensive xenobiotic defenses. Thus, nemadipine is a
unique reagent to genetically probe interactions between DHPs
and Cav1 channels in vivo.
Here, we present our genetic screen of 440,000 mutant C. elegans
genomes for animals that are resistant to nemadipine. Strikingly,
30 of the 35 mutants that we characterized have missense
polymorphisms in the egl-19 gene. Only one of these mutations is
in a non-conserved residue. Eleven of the mutations correspond to
residues of the Cav1 channel that are known to be required for
DHP interaction with mammalian channels. The remaining
mutations are in nine residues not previously associated with
DHP interaction, eight of which are conserved. Behavioral and
developmental analyses of 12 of our worm mutants revealed that
all exhibit phenotypes consistent with increased channel activity.
For seven of these worm mutations, we created orthologous
mutations in the rat brain Cav1.2 channel and examined the
ability of DHPs to block ion current through these mutant
channels using whole-cell voltage clamp analysis in culture. Two of
the mutant channels have decreased sensitivity to the DHP block,
and six disrupt the ability of the DHP to block ion current
completely. Thus, screening for worm mutants that are resistant to
nemadipine is a viable and novel approach to identify mammalian
Cav1 residues that are important for DHP sensitivity.
Results
A Forward Genetic Screen for DHP-Resistant C. elegans
Mutants Yields 30 Polymorphisms in EGL-19
Previous work demonstrated the utility of using C. elegans
calcium channels as a model to better understand mammalian
channel function [30]. We therefore performed a forward genetic
screen for C. elegans mutants that are resistant to nemadipine-
induced growth retardation to identify residues in the Cav1
calcium channel required for DHP sensitivity. A total of 440,000
haploid mutagenized wild type genomes were screened and 55
candidate mutants were isolated. Homozygous lines were
established for 35 of these mutants and polymorphisms were
identified in egl-19 for 30 (Figure 1 and Table 2). Four of the
remaining mutants are genetically linked to egl-19 on chromosome
IV, but no polymorphism in egl-19 could be found (data not
shown). The remaining mutant is not linked to egl-19 and is not
discussed further here. Upon out-crossing select mutants, we found
that all of them exhibited increased resistance to nemadipine in
two separate dose-response assays (Table 2, Figure S1), confirming
that they are indeed DHP-resistant mutants.
The DHP binding site on the Cav1 channel pore-forming a1c-
subunit of vertebrate channels is defined by at least nine residues
that are both necessary and sufficient to confer DHP-sensitivity to
Author Summary
L-type calcium channels are important drug targets
because they regulate many physiological processes
throughout the body. For example, L-type calcium
channels regulate cardiac myocytes and vascular smooth
muscle contraction. Antagonists are therefore commonly
used to lower blood pressure and treat other related
ailments. Despite their medical importance, the mecha-
nism by which L-type antagonists inactivate calcium
channels is not fully understood, due in large part to the
lack of a channel crystal structure. Here, we present the
first large-scale genetic screen for L-type calcium channel
residues that are important for sensitivity to a new drug
analog that we discovered called nemadipine. We
performed the screen using nematodes, and then recre-
ated similar mutations in a mammalian channel to
investigate how the mutant residues alter interactions
with the antagonists using electrophysiological tech-
niques. Together, our analyses revealed eight new L-type
calcium channel residues that are important for DHP-
sensitivity and highlight the utility of using a simple animal
model system for understanding how drugs interact with
their targets.
Cav1.2 Residues Required for DHP Interaction
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residues reside in helix S5 of domain III (called IIIS5), three reside
in IIIS6 and four in IVS6 [12,13,14]. Other studies have shown
the involvement of additional residues required for DHP
interactions (Table 1) [15,18]. From our screen for nemadipine-
resistant mutants, we found ten mutants with polymorphisms
within the IIIS6 domain of EGL-19. Six of these mutate a single
EGL-19 residue, M1056 (rat a1c residue M1161), critical for high-
Figure 1. Topology diagram and sequence alignment of the Cav1 calcium channel a1 subunit. (A) A topology diagram of the C. elegans
Cav1 channel a1 subunit EGL-19 with residues of interest shown. Residues known to be involved in DHP interaction are in red. Blue circles are the
previously characterized hypermorphic residues in EGL-19. Yellow circles are the residues that form the calcium ion filter. Black circles are residues
involved in voltage dependent slow inactivation. Green circles are the EGL-19 polymorphisms isolated in our forward genetic screen and labeled with
the corresponding residue number (worm residue/rat residue) and a star if analyzed further through phenotypic and physiological analyses. See
Tables 1 and 2 for more information about DHP-sensitive residues. (B) Sequence alignment between EGL-19 (GenBank accession number:
NM_001027908) and the orthologous rat brain Cav1.2 a1C subunit (GenBank accession number: M67515). The predicted positions of the
transmembrane segments (IS1-IVS6), channel pore (SS1–SS2) and the EF hand are shown and are based on the EGL-19 sequence[29]. Identical
residues between the two sequences are highlighted in black. An open box beneath the amino acid shows the site of the corresponding coloured
circle from the topology diagram in (A). A black box below the amino acid indicates the sites of the mutations we isolated in EGL-19. The alignment is
shown only slightly past the EF hand as sequence conservation for the C-terminal tail is low after this point.
doi:10.1371/journal.pgen.1000067.g001
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a seventh mutation in EGL-19 residue M1055 (rat a1c residue
M1160) that is also necessary for DHP binding to the vertebrate
channel [11]. An eighth polymorphism was detected in the EGL-
19 residue A1041 (rat a1c residue S1146). Previous work
demonstrated that a rat a1c S1146A mutation does not disrupt
Table 1. A compendium of Cav1.2 residues that may impact DHP interactions in vivo.
Effect Worm Residue
a Rat Residue
b Region Identified in our Screen? Reference
Hypermorphic Channel
G365 G402 IS6 Y Lee et al., 1997
S372 S409 I–II linker - Lee et al., 1997
A906 A1011 IIIS4 - Lee et al., 1997
Required for Slow Inactivation
G365 G402 IS6 Y Splawski et al., 2005
S368 S405 IS6 - Shi & Soldatov, 2002
G369 G406 IS6 - Splawski et al., 2004
I701 I751 IIS6 - Hohaus et al., 2005
A702 A752 IIS6 Y Soldatov et al., 2000
V1063 V1168 IIIS6 - Shi & Soldatov, 2002
I1064 I1169 IIIS6 - Shi & Soldatov, 2002
I1364 I1478 IVS6 - Shi & Soldatov, 2002
Required for Allosteric Enhancement of DHP Interaction by Calcium Occupancy
E326 E363 ISS1–SS2 - Peterson & Catterall, 2006
E656 E706 IISS1–SS2 - Peterson & Catterall, 2006
F1007 F1112 IIISS1–SS2 - Peterson & Catterall, 2006
S1010 S1115 IIISS1–SS2 Y Yamagushi et al., 2000, 2003
F1012 F1117 IIISS1–SS2 - Peterson & Catterall, 2006
E1013 E1118 IIISS1–SS2 - Peterson & Catterall, 1995
Y1020 Y1125 IIISS1–SS2 - Peterson & Catterall, 2006
E1302 E1419 IVSS1–SS2 - Peterson and Catterall, 1995
Required for DHP Interaction
P344 P381 IS6 - Lacinova et al., 1999
I346 V383 IS6 - Lacinova et al., 1999
V349 V386 IS6 - Lacinova et al., 1999
T350 S387 IS6 - Lacinova et al., 1999
T934 T938 IIIS5 - Mitterdorfer et al., 1996
Q1039 Q1043 IIIS5 - Wappl et al., 2001
F1047 Y1152 IIIS6 - Hockerman et al., 1997
I1048 I1153 IIIS6 - Hockerman et al., 1997
I1051 I1156 IIIS6 - Hockerman et al., 1997
F1053 F1158 IIIS6 - Hockerman et al., 1997
F1054 F1159 IIIS6 - Hockerman et al., 1997
M1055 M1160 IIIS6 Y Hockerman et al., 1997
M1056 M1161 IIIS6 Y Hockerman et al., 1997
V1060 V1165 IIIS6 Y Wappl et al., 2001
I1346 I1460 IVS6 - Peterson et al., 1996
F1349 Y1463 IVS6 - Hockerman et al., 1997
M1350 M1464 IVS6 - Hockerman et al., 1997
V1356 I1470 IVS6 - Hockerman et al., 1997
I1357 I1471 IVS6 - Hockerman et al., 1997
N1358 N1472 IVS6 - Hockerman et al., 1997
aThe numbers are based on the worm Cav1 channel (EGL-19) protein sequence (GenBank NM_001027908).
bThe numbers are based on the rat brain Cav1.2 a1C subunit protein sequence (GenBank M67515).
doi:10.1371/journal.pgen.1000067.t001
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alanine is conserved in some Cav1 channels [25]. However, no one
has yet tested if other residues in position 1146, such as the valine
substitution found in our mutant, would disrupt interactions with
DHPs. Finally, two polymorphisms were identified in the EGL-19
residue V1060 (rat a1c residue V1165) within IIIS6 that has yet to
be tested for its role in DHP block. Our finding that seven of the
ten mutations that we identified within the IIIS6 region are
required for DHP-interaction in mammalian Cav1.2 channels
validates our genetic approach for identifying residues required for
DHP-sensitivity, and suggests that the new residues we uncovered
are also important determinants of DHP sensitivity.
High-affinity DHP binding is coupled to the interaction
between the selectivity filter in the outer pore of the a1 subunit
and calcium ions (see introduction). Mutating the glutamate
residues and several of the surrounding residues of the selectivity
filter not only dramatically reduces the binding of calcium ions,
but disrupts DHPs calcium-dependent affinity for the channel
Table 2. A list of previously known and newly identified egl-19 alleles.
allele worm mutation
a rat residue
a region mutated DHP-associated?
b Egl IC50
c Vab IC10
c
- wild-type - - - 1.2 2.1
*ad695 A906V A1011 IIIS4 Y [27] 50 32
*n2368 G365R G402 IS6 Y [27] ..50 ..50
*ad1006 -- -- ,,0 uM 0.2 uM
*n582 A899H R1004 IIIS4 - ,,0 uM 0.2 uM
*tr81 A236V *A283 IS5 N 9 39
tr134 G365R G402 IS6 Y [27] - -
tr135 G365R G402 IS6 - - -
tr136 G365R G402 IS6 - - -
*tr73 A615V *S666 IIS5 N ,50 ..50
*tr93 A615V S666 IIS5 - ,50 ..50
tr72 I652F, V679I I702, V729 IISS1–SS2, IIS6 N/N - -
*tr79 A702T *A752 IIS6 N ..50 ..50
tr84 A702T A752 IIS6 - - -
*tr132 A702T A752 IIS6 - ..50 ..50
tr85 A702V A752 IIS6 - - -
*tr76 A702V *A752 IIS6 - ..50 ..50
*tr86 A702V A752 IIS6 - ..50 ..50
tr87 A702V A752 IIS6 - - -
tr88 A702V A752 IIS6 - - -
tr70 S1010L S1115 IIISS1–SS2 Y [25] - -
tr75 S1010L S1115 IIISS1–SS2 - - -
tr77 A1041V S1146 IIIS6 N - -
*tr92 M1055L *M1160 IIIS6 Y [14] .50 ..50
*tr69 M1056I *M1161 IIIS6 Y [14] .50 ..50
*tr89 M1056I M1161 IIIS6 - ,50 ..50
tr90 M1056I M1161 IIIS6 - - -
tr137 M1056I M1161 IIIS6 - - -
tr138 M1056I M1161 IIIS6 - - -
tr91 M1056I M1161 IIIS6 - - -
*tr71 V1060L *V1165 IIIS6 Y [18] 3 ..50
tr78 V1060G V1165 IIIS6 - - -
*tr74 T1066I *T1171 c-term IIIS6 N 7.75 .50
tr139 E1079K E1184 c-term IIIS6 N - -
tr140 G1594D n.a. c-term tail N - -
aResidues numbered as in Table 1.
bIf the residue was previously implicated in DHP-sensitivity, a ‘Y’ (yes) is displayed along with the reference.
cThe Egl IC50 and the Vab IC10 are determined from nemadipine dose response assays measuring the number of egg laying defective (Egl) animals and animals with
variable abnormal morphology (Vab) as described in Materials and Methods.
*These are the alleles that are further characterized through phenotypic and physiological analyses.
doi:10.1371/journal.pgen.1000067.t002
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channel that precedes the key glutamate in domain III has been
shown to be necessary for DHP-sensitivity (Figure 1, Table 1)
[25,26]. We found that two of the nemadipine-resistant mutants
are polymorphic within the EGL-19 residue S1010 that is
equivalent to the rat a1c residue S1115 (Figure 1; Table 2). We
also isolated a mutant with a polymorphism in a similar position in
domain II (EGL-19 residue I652; rat a1c residue I702). However,
this mutant had a second polymorphism in V679 (rat residue
V729), confounding the attribution of any mutant property to
either polymorphism. Nevertheless, these results suggest that
disrupting residues within the outer pore can reduce DHP-
sensitivity in vivo.
DHP antagonists have high affinity for Cav1 channels in the
inactive state [31]. After voltage dependent opening of the
channel, the channel is coordinately inactivated by both
calcium-dependent and voltage dependent mechanisms. Previous
work has shown that voltage dependent slow inactivation of
Cav1.2 channels is mediated by hydrophobic residues in the
cytoplasmic end of the S6 transmembrane helices of domains I-IV
[32,33,34]. Together, these residues are thought to form a
hydrophobic voltage-sensitive annulus, the disruption of which
leads to prolonged activation of the channel. We found 8
nemadipine-resistant mutants with a polymorphism in EGL-19
A702 within IIS6, which is orthologous to the residue in
vertebrates (rat a1c residue A752) that is most important in slow
inactivation [32]. We also found two mutants with a polymor-
phism in the hydrophobic residue V1060 in the IIIS3 domain of
EGL-19, which precedes an orthologous residue that contributes
to slow inactivation by three positions (rat a1c residue V1168) [33]
(Figure 1, Table 1). We also found three mutants with a
polymorphism in the hydrophobic residue G365 (rat a1c residue
G402) of domain IS6 that is also required for voltage dependent
slow inactivation [5,35]. The same G365R mutation that we
isolated was found independently by Michael Hengartner and
shown to prolong the activation phase of the mutant EGL-19
channel by Raymond Lee and colleagues in vivo [29]. Importantly,
the isolation of at least eleven mutants within the voltage-sensitive
annulus suggests that DHP-blockage is linked to voltage dependent
slow inactivation in vivo.
Finally, we identified seven other mutants that have polymor-
phisms in six residues within regions of the Cav1 channel that have
little functional annotation (A236, A615, V679, T1066, E1079,
and G1594) (Figure 1, Table 2). Of note, two of these mutant
residues are in analogous positions in IS5 and IIS5 (A236 and
A615, respectively). Five of the six mutant residues are in highly
conserved regions of the channel. The sixth mutant residue
(G1594D) is in the carboxy-terminal tail, whose sequence is
evolutionarily divergent (Figure 1). We have further investigated
three of these mutants through both phenotypic and electrophys-
iological analysis as described below.
DHP-Resistant Channels Have Increased Activity in vivo
In contrast to traditional electrophysiological approaches that
rely on transgenics to investigate DHP interactions, our genomic
mutations provided us with a unique opportunity to investigate the
consequences of these polymorphisms on channel activity within
the context of a whole animal. We reasoned that phenotypic
analysis could be used to approximate the level of Cav1 mutant
channel activity in vivo because the level of Cav1 EGL-19 channel
activity has dramatic consequences on the development and
behavior of the animals [27,29]. For example, reduction-of-
function mutations or hypomorphs, such as egl-19(n582), are long
and flaccid. By contrast, mutant channels that have a prolonged
activation phase in electrophysiological studies, such as the egl-
19(n2368) hypermorphic mutant, are myotonic and consequently
shorter than wild type (Figures 2 and 3) [29]. The defects in body
size and rigidity in egl-19 mutants are likely due to altered EGL-19
function in the 95 striated muscles that line the body wall of the
worm. The more active the channel, the more pronounced the
body size phenotypes become [27,29]. Thus, if the nemadipine-
resistant mutants have unaltered behaviors compared to the wild-
type, we might infer that these residues might directly alter DHP
binding without altering channel activity. Alternatively, if the
nemadipine-resistant mutants behaved more like hypermorphs,
then the mutant residues might prolong the activation phase of the
channel and confer DHP-resistance indirectly. Hypomorphic
mutations were neither expected nor observed, since even weak
egl-19 reduction-of-function mutations dramatically decrease the
viability of animals on nemadipine and would not be recovered in
our screen [27].
We began our phenotypic analysis by examining the body
length of twelve of our mutant strains (Table 2, Figure 3). We
chose these 12 mutants because some represent residues that are
known to be required for DHP interaction in other systems (worm
alleles tr92, tr69, tr89, and tr71), while the remaining ones represent
potentially new residues not previously implicated in DHP-
sensitivity. We measured the length of 20 young adults for each
strain and compared their lengths to wild type worms and
previously isolated egl-19 hypermorphs and hypomorphs. None of
our twelve mutants were as short as either the weak (ad695) or the
strong hypermorph (n2368) (Figure 3). However, two of our
mutants were significantly shorter than wild type animals
(p,0.001), suggesting that they might be hypermorphic.
Next, we examined behaviors that have a greater dynamic
range between wild type animals and previously characterized egl-
19 mutants, as these may be more sensitive to changes in EGL-19
activity. For example, egl-19 hypomorphs accumulate two-fold or
more embryos than the wild-type. Conversely, egl-19 hypermorphs
retain approximately two-fold fewer embryos than the wild-type
control (Figures 2 and 3). egl-19 plays important roles in several
cells of the egg-laying circuit, including the eight vulval muscle
cells that directly control vulva opening during embryo deposition
[27,29,36]. Two thirds of our nemadipine-resistant mutants
behaved similar to the egl-19 hypermorphs, retaining significantly
fewer embryos than the wild-type (p,0.001), consistent with the
idea that these mutants are also hypermorphic (Figure 3).
Although all of our 12 egl-19 alleles that we examined exhibit
the same trends in the length and egg-retention assays, it is unclear
to us why tr81 and tr86 behave slightly differently. It may be that
background mutations have a mild influence on these two
behaviors in these two mutants. As expected, we found a positive
correlation (0.64) between the strength of the egg-laying
phenotype and the degree of resistance to nemadipine (Table S1).
Finally, we examined how our mutants affect the contraction of
a specialized set of muscles in the male tail that regulate spicule
protrusion. The spicules are a pair of sclerotized cuticle structures
that are housed in the male tail and used during the transfer of
sperm to hermaphrodites [37] (Figure 2). The protrusion of each
spicule is controlled by a pair of protraction and retraction
muscles. egl-19 is a key regulator of spicule-associated muscles and
functions autonomously to regulate their contraction [38]. Nearly
all males of a previously characterized egl-19 hypermorph have
protruded spicules, called a Prc phenotype, while egl-19 hypo-
morphic males cannot protrude their spicules (Figure 2 and 3)
[29,38]. We found that all of our nemadipine-resistant mutants
were obviously Prc (Figure 3). The Prc phenotype of all egl-19
alleles examined was suppressed by nemadipine (Figure 3).
Cav1.2 Residues Required for DHP Interaction
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constitutive egg-laying phenotypes of our egl-19 mutants
(Figure 3). This demonstrates that the observed spicule protrusion,
constitutive egg-laying and shortened length phenotypes are all
mediated by increased egl-19 activity. It is noteworthy that the egl-
19 mutations that correspond to the rat a1c residues M1160,
M1161, and V1165, which are necessary for high-affinity DHP
binding [12,13,14], also show increased EGL-19 channel activity.
Together, our phenotypic analyses suggest that our nemadipine-
resistant mutants have increased channel activity in vivo.
EGL-19 Polymorphic Residues Are also Required for
Complete Current Block of Mammalian Cav1.2 Channels
by DHPs
We tested if the mutant residues of EGL-19, which confers
DHP-resistance and increased channel activity in worms, also alter
DHP-sensitivity of a mammalian Cav1.2 channel. We created
orthologous mutations in the a1C subunit of the rat Cav1.2 channel
and transiently expressed these in tsA201 cells along with auxiliary
Cav1.2 channel components b2a and a2-d [39,40]. Ion currents
through both wild-type and mutant channels were then measured
in the presence of increasing concentrations of nifedipine, a
popular DHP, using whole-cell voltage-clamp electrophysiological
techniques (see methods for details). In this way, we could
determine if the orthologous rat mutations affect the ability of
DHPs to block Cav1.2 channel-mediated ionic current.
We first examined polymorphisms in domain IIIS6 residues
previously shown to be required for DHP binding. As a positive
control, we created a rat a1C M1161A mutation that is known to
disrupt the high-affinity interaction between DHPs and the Cav1.2
channel [11,14]. The M1161A mutation increased the IC50 of
nifedipine block ,100-fold compared to the wild type channel,
confirming the importance of this residue in DHP sensitivity
(Figure 4). The nearby V1165L mutation also increases the IC50 of
nifedipine block by about 30-fold, consistent with its role in high-
affinity DHP interactions [18]. Curiously, a leucine substitution in
residue M1160, which is also required for DHP interaction [11],
did not increase the IC50 of nifedipine block (Figure 4). T1171I,
which is cytoplasmic and follows the IIIS6 transmembrane
domain, also did not exhibit a shift in the IC50. However, both
M1160L and T1171I exhibited large residual currents at 100 mM
nifedipine, which is sufficient to completely block the ion current
through wild type channels (Figure 4). The validity of the residual
current was further supported by a comparison to the complete
block of current through the respective wild-type and mutant
channels by 10 mM cadmium, which is a non-selective pore
blocker commonly used to block all current through Cav1
channels [41].
Figure 2. Comparisons of the phenotypes analyzed in C. elegans. (A) An N2 adult showing wild-type length and number of embryos (arrow).
(B) An egl-19(tr89) adult is approximately wild-type in length and contains fewer embryos (arrow). (C) A him-5(e1490) adult male showing wild-type
tail morphology with the spicules in the normal retracted position (arrowhead). (D) An egl-19(tr89) adult male often has spicules that are constantly
protracted (arrowhead). All pictures are of animals raised on 0.33% DMSO as L4s. Scale bars, 50 mm.
doi:10.1371/journal.pgen.1000067.g002
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in IS5 (A283V), and IIS5 (A/S666V). Although no significant shift
was observed in the IC50 response to nifedipine for either channel,
the S666V mutant left a significant residual current at saturating
concentrations of nifedipine. It is currently unclear why the
A283V polymorphic channel behaves similar to the wild-type
channel in our assay. Finally, we examined a pair of mutations in a
single residue in IIS6 (A752T/V) that contributes to the
hydrophobic annulus required for voltage dependent slow
inactivation [32]. Consistent with these previous observations,
we found that both A752T and A752V yield a significant residual
current of about 6-8%, likely reflecting the importance of this site
for slow inactivation. Surprisingly, we also found that the IC50 of
nifedipine block for A752V, but not A752T, increases about five-
fold (Figure 4). As expected, we found positive correlations
between the IC50 values of the mutant rat channels on nifedipine
and the degree of resistance by the respective worm mutants on
nemadipine (0.83), and between the amount of residual current of
the mutant rat channels and the degree of resistance of the worm
mutants (0.63) (Table S1).
Figure 3. Phenotypic analysis in C. elegans shows that the nemadipine-resistant egl-19 mutations are hypermorphic. A comparison of
phenotypes in wild type animals (wt), hypermorphs (ad695 and n2368), the hypomorph ad1006, and the nemadipine-resistant mutants isolated in our
screen. (A) The length of mutant worms. (B) The number of embryos in utero of mutant worms. (C) The protruding spicule phenotype of egl-19
mutants. The worm polymorphic residue follows the allele designation in brackets. The dotted lines in (A) and (B) represent the phenotype of wild-
type worms on DMSO. The sickness of egl-19 hypomorphs is exacerbated in the presence of nemadipine, accounting for the trend that is opposite
than expected in the presence of nemadipine in (A) and (B). Asterisks, p,0.001 compared to the negative control in DMSO in (A) and (B), and p,0.05
for (C). Error bars, 6s.e.m.
doi:10.1371/journal.pgen.1000067.g003
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DHP-sensitivity as indicated by an increased IC50 for the DHP-
block, and six of the seven mutant channels resist a completely
blocked state. These electrophysiology results therefore demon-
strate that the identification of Cav1.2 residues that are required
for DHP-sensitivity in the worm can reveal residues that are also
important for mammalian DHP-sensitivity.
Discussion
Here, we set out to identify Cav1 residues that are important for
DHP sensitivity in vivo through a forward genetic screen. Our
approach was made possible through our discovery of nemadipine,
which is the only DHP known to robustly antagonize Cav1
channels within the context of undissected C. elegans worms [27].
By screening for mutants that are resistant to the effects of
nemadipine, we identified 30 independent Cav1 polymorphisms
that reduce DHP-sensitivity. Upon further investigating 12 of
these, we found that all likely increase channel activity in whole
worms. Further investigation of how these mutant residues alter
the response of a mammalian ortholog to DHP-treatment not only
led us to new residues required for DHP sensitivity, but provides in
vivo support for a previously established idea that the DHP block
likely requires voltage dependent inactivation of the channel (see
below).
Evidence suggests that at least five of the 14 Cav1 polymorphic
residues that we identified are required for physical interactions
with DHPs. Four of the residues we identified (corresponding to
rat a1c residues S1115, M1160, M1161, and V1165) were
previously shown to decrease DHP affinity for the channel when
mutated [14,18,25]. Additionally, two mutant residues (corre-
sponding to rat a1c residues A752V and V1165L) showed a
significant increase in the IC50 response to nifedipine in our
electrophysiology assay. The observed shift in the IC50 is consis-
tent with a decrease in the affinity of the DHP for the mutant
channels.
Previous biochemical analyses identified residues within IS6
[15], IIIS5, IIIS6, and IVS6 [11,16] that are important for DHP
binding. However, our genetic screen did not reveal polymor-
phisms in many of these residues. One reason for this is that our
screen was not done to saturation; only six of the 14 residues
identified are represented by multiple alleles. It is therefore likely
that several residues required for DHP sensitivity in vivo remain
unidentified, which is proven by the absence of the previously
identified A906V nemadipine-resistant mutation [27,29] from our
screen. Second, many of the residues not identified in the genetic
screen play only ancillary or weak roles in DHP binding, including
those of IS6 [15] and IVS6 [11] and may not confer DHP-
resistance by themselves in vivo. Third, polymorphisms in each of
several IVS6 residues involved in DHP-binding significantly
Figure 4. Concentration-dependent block effect of nifedipine on the rat CaV1.2 a1C mutant L-type channels (co-expressed with b2a
and a2d). Representatives of barium current records in various nifedipine concentrations (A, C, E) and the mean concentration-effect curves (B, D, F).
A & B: the wildtype (WT) and domain III mutants; C. & D: Domain II mutants; and E & F: domain I mutant. The nifedipine concentrations ranged 0, 0.1,
1, 10, 30, 100 mM. The current was elicited by an 80 ms +10 mV depolarizing pulse from a holding potential of 2100 mV. In all traces, the baseline
was determined by block by 10 mM cadmium (trace with ,0 pA current). The nifedipine effect was normalized to the unblocked current (Imax)
obtained in the absence of the drug. The concentration-effect curves were fit to a modified Hill equation taking into account the possibility of
incomplete current block, as described in the methods. The mean concentration-effect curve for the M1161A mutant, known to be important for DHP
block[11,14], serves as a positive control. Summaries of the IC50 values (G), and the residual unblocked current measured at 100 mM nifedipine (H),
obtained from the same data presented in Figure B, D, and F. The fraction of current remaining at 100 mM nifedipine (Funblock (I100/Imax)) was used to
estimate the completeness of drug block. All the data are presented as mean6s.e.m.; numbers in the parentheses in G reflects the number of
independent experiments. * indicates statistical significance relative to the wildtype (p,0.05, one-way ANOVA, post-hoc Holm-Sidak).
doi:10.1371/journal.pgen.1000067.g004
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function mutations would not be recovered in our forward genetic
screen. Fourth, nemadipine may interact with EGL-19 in slightly
different ways compared to how canonical DHPs interact with
mammalian channels. If true, this difference might prevent the
recovery of mutations of some residues required for high affinity
DHP interactions with mammalian channels in our worm screen.
However, it remains possible that many of the Cav1.2 residues
shown to be required for high-affinity DHP interactions in culture
play little or no role in DHP interactions in vivo. Regardless, our
finding that polymorphisms in S1115, M1160, M1161 and V1165
do confer DHP-resistance in vivo adds further weight to existing
biochemical and electrophysiological evidence that these residues
are critical for DHP interactions.
Several lines of evidence from our work support the previously
established idea that DHP-sensitivity of the channel is intimately
associated with voltage dependent inactivation [18,19]. First, our
behavioral analyses of mutant worms reveals that polymorphisms
within or near the predicted hydrophobic annulus (corresponding
to rat a1C polymorphisms G402R, A752T, A752V, V1165L, and
T1171I), which are normally required to block the channel
through voltage dependent slow inactivation, decrease DHP-
sensitivity and increase channel activity in vivo. Second, electro-
physiological analysis on four of these polymorphisms (A752T,
A752V, V1165L, and T1171I) reveal significant residual current
in the presence of DHP concentrations that is sufficient to block
the wild-type channel in culture and two of these polymorphisms
(A752T and T1171I) do not show any change in the IC50 for the
DHP-block. This suggests that these residues are required to
engage the DHP-block without being involved in DHP-sensitivity.
Because the A752T mutation is known to disrupt voltage-gated
slow inactivation [32] (and T1171 is very close to V1168 and
I1169 that are also required for voltage-gated slow inactivation
[33]), our observations provide additional support for the
previously established idea that the DHP block may be mediated
through the same mechanism employed by voltage-gated slow
inactivation [18,19]. Together, our work demonstrates that a
forward genetic screen for worms resistant to DHPs is a viable
approach for the discovery of residues that are important for
mammalian DHP-sensitivity.
Materials and Methods
Screening, Mapping, and Phenotypic Analysis of
Nemadipine-Resistant Mutants
Candidate mutants were isolated and mapped through their
resistance to nemadipine-induced population growth defect as
described previously [27,28]. For this work, we used only the
nemadipine-A analog, simply referred to as nemadipine here. To
determine the IC50 and IC10 of the mutants with respect to the
egg-laying-retention (Egl) phenotype and the variable abnormal
(Vab) morphological defects induced by the compound, a
population enriched for adults for each mutant strain was chunked
onto MYOB plates containing either nemadipine or only the
DMSO solvent as the negative control [28]. Approximately
24 hours later, young adults were picked on to a new nemadipine
or DMSO plates. For the Egl assay, adults were scored as either
being Egl or non-Egl approximately 24 hours later. For the Vab
assay, the L1 and L2 larvae laid by the adults were scored for
morphological defects approximately 24 hours later.
To measure length and count embryos in utero, roughly 100 L4s
of each strain were picked onto plates containing either DMSO or
5 mM nemadipine. Approximately 24 hours later, resulting young
adults were photographed at 206 using a Leica MZFLIII
microscope with a Retiga 1300 digital camera (Q Imaging). The
lengths were measured using Openlab software (Improvision, Inc.).
Embryos in utero were counted approximately 24 hours after the
L4s were place on the plates using a Leica MZFLIII microscope at
approximately 806 magnification. For the protruding spicule
counts, him-5(e1490) doubles were created for each strain. L4
males were picked and put onto either DMSO or 5 mM plates.
Approximately 24 hours later, the males were scored as either
having protruding spicules (Prc) or non-Prc.
Creating the Homologous Mutation in the Rat Brain
Cav1.2 Channel
The rat brain L-type a1C subunit in pMT2 and b2a and a2d
were generous gifts of Dr. Terry Snutch (University of British
Columbia, Vancouver, Canada). The a1C subunit was divided into
3 fragments based on endogenous restriction sites: KpnI in pMT2,
SalI in a1C, SpeI in a1C, and a second SpeI in the 39 untranslated
region of a1C. The first fragment of size 2.5 kB from KpnI
(pMT2)-SalI spanned the N-terminus up to domain II S6 of the
channel. The last fragment of size 4 kB from SpeI-SpeI (in the 39
untranslated region) spanned domain IIIS1 to the end of the C-
terminus. Both of these fragments were separately subcloned into
pBluescript SK+ (Stratagene). Specific mutagenic primers (Table
S2) were designed and used in PCR-directed mutagenesis on the
subcloned fragments using Stratagene’s Site-directed Mutagenesis
Kit. M1160L and M1161A were created using the GeneEditor
Site Directed Mutagenesis Kit (Promega) with the following
primers: M1160L (59- CATTGCCTTCTTCCTGATGAA-
CATC-39) and M1161A (59-CATTGCCTTCTTCATGGC-
CAACATCTTCGTGGG-39). Fragments were subcloned back
into the parent a1C subunit in pMT2, and the mutations were
confirmed by DNA sequencing.
Cell Culture, Transfection, Electrophysiology, and Data
Analysis
Cell culture and transfection using tsA201 cells are presented in
the SI materials and were done as previously described [39,40].
Whole-cell (ruptured) recordings were performed on an Axopatch
700A amplifier linked to a personal computer equipped with
pClamp9 (Axon Instruments, Foster City, CA). Patch pipettes
(Sutter, BF 150-86-15) were pulled using a Sutter P-87
microelectrode puller and polished with a Narashige microforge
[39,40]. Pipettes (2–4 MV) were filled with (in mM) 140 Cs-
methanesulfonate, 4 MgCl2, 9 EGTA, 9 HEPES (pH 7.2 adjusted
with CsOH). Bath recording solution comprised of (in mM) 20
BaCl2, 85 CsCl, 40 TEA-Cl, 1 MgCl2, 10 HEPES, 10 glucose
(pH 7.3 adjusted with CsOH). Perfusions consisted of bath
solution with various concentrations of DHP from 0.01 mMt o
100 mMo r1 0mM CdCl2, and applied using a gravity-driven
system. In some cases, 0.1% DMSO was added to the control bath
solution (no drug). Data were filtered at 1 kHz (23 dB, 4-pole
Bessel) and digitized at 2 kHz. Currents were elicited by stepping
from 2100 mV to the indicated test potentials. Drug-response
curve were determined by depolarizing to elicit maximal inward
Ba
2+ currents (usually 0 to +10 mV) every 5 seconds, first
perfusing with control solution and then with various concentra-
tions of DHP compounds until the current amplitude reached a
steady-state level. Recordings were done with Ba
2+as Ca
2+ may
greatly affect current through mechanisms such as Ca
2+-
dependant inactivation or Ca
2+-dependant facilitation [42].
Channel behavior was otherwise normal in the mutants as Ba
2+
current through the mutant channels were elicited at the range of
applied voltages from 230 to +40 mV, which is similar to that of
Cav1.2 Residues Required for DHP Interaction
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equation:
IBa

IBa control ðÞ ~Fresidualz1= 1z C=IC50 ðÞ
n ðÞ
Where IBa is the current recorded either in the absence (IBa(control))
or the presence of drug; Fresidual is the fraction residual current at
saturated concentrations of DHP; C is the concentration of DHP;
IC50 is the DHP concentration required to elicit half the maximal
inhibition; and n is the Hill coefficient (see Table S3 for more
information). As DHPs do not physically occlude the pore [43]
Fresidual was included in the analyses so that the estimated IC50
accurately represents the interaction with the channel and not
confounded by the efficacy of the block. Fits were performed in
Origin 7 (OriginLab Corp., Northampton, MA). All experiments
were performed at room temperature (,22uC). Data are presented
as mean6sem. Statistical analysis was done using one-way analysis
of variance (ANOVA, Holm-Sidak post-hoc). Differences were
considered significant if p,0.05.
Chemicals and Solutions
All chemicals used in the cell culture were purchased from
GIBCO (Invitrogen). Chemicals used for physiological recordings
were purchased from Sigma. Nifedipine was purchased from
Alamone Labs (Jerusalem, Israel) and from Sigma, and nemadi-
pine was purchased from Chembridge Corp. (Chembridge ID#:
5619779).
Supporting Information
Figure S1 Animals with egg laying (Egl) defects and variable
abnormal (Vab) defects in response to increasing concentrations of
nemadipine. (a) Dose response curves for the tr89, the domain I
mutant, ad695 and n2368, the egl-19 hypermorphs, and N2, the
wild-type control. (b) Dose response curves for domain II mutants.
(c) Dose response curves for domain III mutants. All the mutants
analyzed in the Egl and Vab assays have increased resistance to
nemadipine compared to N2 showing that these mutants are
DHP-resistant. The Egl and Vab assays were performed as
outlined in Materials and Methods. Error bars, 6s.e.m.
Found at: doi:10.1371/journal.pgen.1000067.s001 (2.23 MB EPS)
Table S1 An excel file of the calculations of correlations between
the worm phenotypes and the behavior of the mutant rat channels.
Found at: doi:10.1371/journal.pgen.1000067.s002 (0.17 MB
XLS)
Table S2 Primers used in PCR-directed mutagenesis of rat
alpha 1C mutants. Bold letter indicate mutations. Primers listed
from 59 to 39.
Found at: doi:10.1371/journal.pgen.1000067.s003 (0.04 MB
DOC)
Table S3 An excel file of the Hill coefficients of the rat channel
variants in response to nifedipine.
Found at: doi:10.1371/journal.pgen.1000067.s004 (0.02 MB
XLS)
Acknowledgments
We would like to thank Zobia Jawed, Jessica Leen, Julie Turnbull, and
Jennifer Shing for technical assistance, Terry Snutch for sharing transgene
reagents, Andrew Spence for helpful comments on the work, and Theresa
Stiernagle and the C. elegans Genetic Center, which is funded by the NIH
National Center for Research Resources, for providing worm strains to us.
Author Contributions
Conceived and designed the experiments: TK KH PR. Performed the
experiments: TK KH WK NR GS ZF. Analyzed the data: TK KH PR.
Wrote the paper: TK KH PR.
References
1. Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of
calcium signalling. Nat Rev Mol Cell Biol 1: 11–21.
2. Catterall WA (2000) Structure and regulation of voltage-gated Ca2+ channels.
Annu Rev Cell Dev Biol 16: 521–555.
3. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J (2005) International
Union of Pharmacology. XLVIII. Nomenclature and structure-function
relationships of voltage-gated calcium channels. Pharmacol Rev 57: 411–425.
4. Sonkusare S, Palade PT, Marsh JD, Telemaque S, Pesic A, et al. (2006) Vascular
calcium channels and high blood pressure: pathophysiology and therapeutic
implications. Vascul Pharmacol 44: 131–142.
5. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, et al. (2004)
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including
arrhythmia and autism. Cell 119: 19–31.
6. Bech-Hansen NT, Naylor MJ, Maybaum TA, Pearce WG, Koop B, et al. (1998)
Loss-of-function mutations in a calcium-channel alpha1-subunit gene in
Xp11.23 cause incomplete X-linked congenital stationary night blindness. Nat
Genet 19: 264–267.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 289:
2560–2572.
8. Tang S, Yatani A, Bahinski A, Mori Y, Schwartz A (1993) Molecular
localization of regions in the L-type calcium channel critical for dihydropyridine
action. Neuron 11: 1013–1021.
9. Grabner M, Wang Z, Hering S, Striessnig J, Glossmann H (1996) Transfer of
1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels.
Neuron 16: 207–218.
10. Schuster A, Lacinova L, Klugbauer N, Ito H, Birnbaumer L, et al. (1996) The
IVS6 segment of the L-type calcium channel is critical for the action of
dihydropyridines and phenylalkylamines. Embo J 15: 2365–2370.
11. Peterson BZ, Johnson BD, Hockerman GH, Acheson M, Scheuer T, et al. (1997)
Analysis of the dihydropyridine receptor site of L-type calcium channels by
alanine-scanning mutagenesis. J Biol Chem 272: 18752–18758.
12. Sinnegger MJ, Wang Z, Grabner M, Hering S, Striessnig J, et al. (1997) Nine L-
type amino acid residues confer full 1,4-dihydropyridine sensitivity to the
neuronal calcium channel alpha1A subunit. Role of L-type Met1188. J Biol
Chem 272: 27686–27693.
13. Ito H, Klugbauer N, Hofmann F (1997) Transfer of the high affinity
dihydropyridine sensitivity from L-type To non-L-type calcium channel. Mol
Pharmacol 52: 735–740.
14. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA (1997) Molecular
determinants of drug binding and action on L-type calcium channels. Annu Rev
Pharmacol Toxicol 37: 361–396.
15. Lacinova L, Klugbauer N, Hu M, Hofmann F (1999) Reconstruction of the
dihydropyridine site in a non-L-type calcium channel: the role of the IS6
segment. FEBS Lett 451: 152–156.
16. Peterson BZ, Tanada TN, Catterall WA (1996) Molecular determinants of high
affinity dihydropyridine binding in L-type calcium channels. J Biol Chem 271:
5293–5296.
17. Mitterdorfer J, Wang Z, Sinnegger MJ, Hering S, Striessnig J, et al. (1996) Two
amino acid residues in the IIIS5 segment of L-type calcium channels
differentially contribute to 1,4-dihydropyridine sensitivity. J Biol Chem 271:
30330–30335.
18. Wappl E, Mitterdorfer J, Glossmann H, Striessnig J (2001) Mechanism of
dihydropyridine interaction with critical binding residues of L-type Ca2+
channel alpha 1 subunits. J Biol Chem 276: 12730–12735.
19. Berjukow S, Marksteiner R, Gapp F, Sinnegger MJ, Hering S (2000) Molecular
mechanism of calcium channel block by isradipine. Role of a drug-induced
inactivated channel conformation. J Biol Chem 275: 22114–22120.
20. Glossmann H, Ferry DR, Goll A, Striessnig J, Zernig G (1985) Calcium channels
and calcium channel drugs: recent biochemical and biophysical findings.
Arzneimittelforschung 35: 1917–1935.
21. Peterson BZ, Catterall WA (2006) Allosteric interactions required for high-
affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are
modulated by calcium in the pore. Mol Pharmacol 70: 667–675.
22. Wang X, Du L, Peterson BZ (2007) Calcicludine binding to the outer pore of L-
type calcium channels is allosterically coupled to dihydropyridine binding.
Biochemistry 46: 7590–7598.
23. Mitterdorfer J, Sinnegger MJ, Grabner M, Striessnig J, Glossmann H (1995)
Coordination of Ca2+ by the pore region glutamates is essential for high-affinity
Cav1.2 Residues Required for DHP Interaction
PLoS Genetics | www.plosgenetics.org 11 May 2008 | Volume 4 | Issue 5 | e1000067dihydropyridine binding to the cardiac Ca2+ channel alpha 1 subunit.
Biochemistry 34: 9350–9355.
24. Peterson BZ, Catterall WA (1995) Calcium binding in the pore of L-type
calcium channels modulates high affinity dihydropyridine binding. J Biol Chem
270: 18201–18204.
25. Yamaguchi S, Okamura Y, Nagao T, Adachi-Akahane S (2000) Serine residue
in the IIIS5–S6 linker of the L-type Ca2+ channel alpha 1C subunit is the
critical determinant of the action of dihydropyridine Ca2+ channel agonists.
J Biol Chem 275: 41504–41511.
26. Yamaguchi S, Zhorov BS, Yoshioka K, Nagao T, Ichijo H, et al. (2003) Key
roles of Phe1112 and Ser1115 in the pore-forming IIIS5–S6 linker of L-type
Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and
action of Ca2+ channel agonists. Mol Pharmacol 64: 235–248.
27. Kwok TC, Ricker N, Fraser R, Chan AW, Burns A, et al. (2006) A small-
molecule screen in C. elegans yields a new calcium channel antagonist. Nature
441: 91–95.
28. Burns AR, Kwok TC, Howard A, Houston E, Johanson K, et al. (2006) High-
throughput screening of small molecules for bioactivity and target identification
in Caenorhabditis elegans. Nat Protoc 1: 1906–1914.
29. Lee RY, Lobel L, Hengartner M, Horvitz HR, Avery L (1997) Mutations in the
alpha1 subunit of an L-type voltage-activated Ca2+ channel cause myotonia in
Caenorhabditis elegans. Embo J 16: 6066–6076.
30. Mathews EA, Garcia E, Santi CM, Mullen GP, Thacker C, et al. (2003) Critical
residues of the Caenorhabditis elegans unc-2 voltage-gated calcium channel that
affect behavioral and physiological properties. J Neurosci 23: 6537–6545.
31. Bean BP (1984) Nitrendipine block of cardiac calcium channels: high-affinity
binding to the inactivated state. Proc Natl Acad Sci U S A 81: 6388–6392.
32. Soldatov NM, Zhenochin S, AlBanna B, Abernethy DR, Morad M (2000) New
molecular determinant for inactivation of the human L-type alpha1C Ca2+
channel. J Membr Biol 177: 129–135.
33. Shi C, Soldatov NM (2002) Molecular determinants of voltage-dependent slow
inactivation of the Ca2+ channel. J Biol Chem 277: 6813–6821.
34. Hohaus A, Beyl S, Kudrnac M, Berjukow S, Timin EN, et al. (2005) Structural
determinants of L-type channel activation in segment IIS6 revealed by a retinal
disorder. J Biol Chem 280: 38471–38477.
35. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, et al. (2005) Severe
arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc
Natl Acad Sci U S A 102: 8089–8096; discussion 8086–8088.
36. Waggoner LE, Zhou GT, Schafer RW, Schafer WR (1998) Control of
alternative behavioral states by serotonin in Caenorhabditis elegans. Neuron 21:
203–214.
37. Sulston JE, Albertson DG, Thomson JN (1980) The Caenorhabditis elegans
male: postembryonic development of nongonadal structures. Dev Biol 78:
542–576.
38. Garcia LR, Mehta P, Sternberg PW (2001) Regulation of distinct muscle
behaviors controls the C. elegans male’s copulatory spicules during mating. Cell
107: 777–788.
39. Feng ZP, Hamid J, Doering C, Bosey GM, Snutch TP, et al. (2001) Residue
Gly1326 of the N-type calcium channel alpha 1B subunit controls reversibility of
omega-conotoxin GVIA and MVIIA block. J Biol Chem 276: 15728–15735.
40. Hui K, Gardzinski P, Sun HS, Backx PH, Feng ZP (2005) Permeable ions
differentially affect gating kinetics and unitary conductance of L-type calcium
channels. Biochem Biophys Res Commun 338: 783–792.
41. Lansman JB, Hess P, Tsien RW (1986) Blockade of current through single
calcium channels by Cd2+,M g 2 +, and Ca2+. Voltage and concentration
dependence of calcium entry into the pore. J Gen Physiol 88: 321–347.
42. Halling DB, Aracena-Parks P, Hamilton SL (2006) Regulation of voltage-gated
Ca2+ channels by calmodulin. Sci STKE 2006: er1.
43. Hockerman GH, Johnson BD, Scheuer T, Catterall WA (1995) Molecular
determinants of high affinity phenylalkylamine block of L-type calcium channels.
J Biol Chem 270: 22119–22122.
Cav1.2 Residues Required for DHP Interaction
PLoS Genetics | www.plosgenetics.org 12 May 2008 | Volume 4 | Issue 5 | e1000067